Abstract: An apparatus for predicting performance of a wheel in a vehicle: includes a learning device that generates a latent space for a plurality of two-dimensional (2D) wheel images based on a convolutional autoencoder (CAE), extracts a predetermined number of the plurality of 2D wheel images from the latent space, and learns a dataset having the plurality of 2D wheel images and performance values corresponding to the plurality of 2D wheel images; and a controller that predicts performance for the plurality of 2D wheel images based on a performance prediction model obtained by the learning device.

Abstract: The present disclosure relates to a simulation apparatus for secondary battery production.

Abstract: There is provided a feed additive composition. The feed additive composition includes one or more selected from beta-glucan and lysophospholipid, and erythritol. One or more selected from 60 to 100 parts by weight of the beta-glucan and 5 to 10 parts by weight of the lysophospholipid are contained with respect to 100 parts by weight of the erythritol. The erythritol comes from a culture medium of a strain producing erythritol.

Abstract: The present disclosure relates to a composition for preventing, alleviating or treating a neurodegenerative disease, which contains Pediococcus inopinatus as an active ingredient. The Pediococcus inopinatus strain according to the present disclosure can suppress neuroinflammation and can also alleviate the symptoms of ataxia in an animal model of Parkinson's disease and, thus, can be utilized for the prevention, alleviation and treatment of various neurodegenerative diseases including Parkinson's disease.

Abstract: The present disclosure relates to a composition for preventing, alleviating or treating depression or anxiety disorder, which contains Lactobacillus sakei as an active ingredient. The Lactobacillus sakei strain according to the present disclosure can be used to prevent, alleviate or treat a mental disorder such as depression or anxiety disorder.

Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, niclosamide or pharmaceutically acceptable salts thereof, for treating or preventing disease related to Axin-GSK3 interaction, such as familial adenomatosis polyposis (FAP). According to the present invention, familial adenomatosis polyposis (FAP) which causes pain due to lack of specific treatment methods, can be effectively treated using niclosamide, which is a safe drug approved by the FDA.

Abstract: Disclosed is a method of providing biological data. The method includes the following steps performed by a data processing device: selecting a biological data set from a biological data pool; encrypting biological data included in the biological data set to produce encrypted biological data; transferring the encrypted biological data to a user; receiving a result of analysis on the encrypted biological data from the user; and transferring information on the encrypted biological data included in the result of the analysis to the user. The data processing device encrypts the biological data with a key determined according to a combination of biological data constituting the biological data set.

Abstract: Disclosed is a method of providing biological data. The method includes the following steps performed by a data processing device: selecting a biological data set from a biological data pool; encrypting biological data included in the biological data set to produce encrypted biological data; transferring the encrypted biological data to a user; receiving a result of analysis on the encrypted biological data from the user; and transferring information on the encrypted biological data included in the result of the analysis to the user. The data processing device encrypts the biological data with a key determined according to a combination of biological data constituting the biological data set.

Abstract: The present invention relates to: a method for providing information for the prediction or diagnosis of oral precancer or oral cancer characterized by confirming expression of the Axin2 gene or the Snail gene in an oral leukoplakia tissue sample or an oral submucous fibrosis tissue sample; and a use of a compound capable of delaying or inhibiting the progression of a precancerous lesion and recurrent oral cancer using the compound capable of effectively inhibiting the expression of the Axin2 gene or the Snail gene. According to the present invention, the possibility of oral leukoplakia or submucous fibrosis which causes white lesions to appear inside the oral cavity can be predicted and diagnosed, thereby being useful in eliminating the potential risks of oral cancer by early prediction of progression into oral precancer or oral cancer for which effective treatment does not currently exist.

Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, niclosamide or pharmaceutically acceptable salts thereof, for treating or preventing disease related to Axin-GSK3 interaction, such as familial adenomatosis polyposis (FAP). According to the present invention, familial adenomatosis polyposis (FAP) which causes pain due to lack of specific treatment methods, can be effectively treated using niclosamide, which is a safe drug approved by the FDA.

Abstract: Provided is a method for manufacturing a printed circuit board. The method for manufacturing the printed circuit board includes applying an adhesive on a support board, attaching an electronic device on the adhesive, forming an insulation layer for burying the electronic device, separating the insulation layer from the support board, forming a lower insulation layer under the insulation layer, and forming a via connected to terminals of the electronic device in the insulation layer or the lower insulation layer. Thus, since an adhesion material of an adhesion film does not remain between the internal circuit patterns, and the internal circuit patterns are not stripped by an adhesion force of the adhesion film, device reliability may be secured.

Abstract: The present invention provides a pharmaceutical composition for preventing or treating angiogenic diseases comprising inhibitors of NUP153 gene expression or NUP153 activity as active ingredient and a method for screening an agent for preventing or treating angiogenic diseases. According to the present invention, inhibition of the NUP153 gene expression or the NUP153 activity reduces export of mRNA of a pro-angiogenic factor (VEGF, HGF and bFGF) from nucleus. In addition, inhibition of the NUP153 gene expression or the NUP153 activity has effect that angiogenesis are inhibited by inhibition of invasion and tube formation in a dose-dependent manner without showing toxicity. Therefore, the pharmaceutical composition of the present invention may be used for preventing or treating a variety of angiogenesis-related diseases, and the method for screening of the present invention may be valuably used in finding a new agent for preventing or treating angiogenic diseases.

Abstract: The present invention relates to an antimicrobial composition including phytic acid and electrolytes.

Abstract: The present invention relates to an antimicrobial composition including phytic acid and electrolytes.

Abstract: An organic light emitting device includes: a first substrate; a plurality of electrodes on the first substrate; a pixel definition layer on the plurality of electrodes and including a plurality of openings and respectively exposing the plurality of electrodes; and a spacer on the pixel definition layer, wherein the pixel definition layer includes a first opening and a second opening adjacent to each other along a first direction by an interval for each pixel, and a third opening adjacent to the first opening and the second opening by an interval along a second direction crossing the first direction, and wherein the spacer is at a crossing point of a first imaginary line extending in the first direction and passing between the first opening and the third opening and a second imaginary line extending in the second direction and passing between the first opening and the second opening.

Abstract: A mobile terminal having a QWERTY key layout and a method of setting and inputting a symbol therein are provided. The method of setting a symbol in a mobile terminal having a QWERTY key layout includes selecting a setting function of a symbol defined a user; adding, if the selected setting function comprises an addition function, a selected symbol to a key mapping table, deleting, if the selected setting function comprises a deletion function, a selected symbol from the key mapping table, and changing, if the selected setting function comprises a change function, a selected symbol to another selected symbol. Therefore, symbols frequently used by a user can be viewed in one screen, thereby minimizing steps for searching for a desired symbol. Further, a symbol set by the user can be immediately determined by displaying symbols mapped to each key of a key input unit with a QWERTY key layout, and thus a character including a symbol can be easily input, thereby improving user convenience.

Abstract: An organic light emitting device includes: a first substrate; a plurality of electrodes on the first substrate; a pixel definition layer on the plurality of electrodes and including a plurality of openings and respectively exposing the plurality of electrodes; and a spacer on the pixel definition layer, wherein the pixel definition layer includes a first opening and a second opening adjacent to each other along a first direction by an interval for each pixel, and a third opening adjacent to the first opening and the second opening by an interval along a second direction crossing the first direction, and wherein the spacer is at a crossing point of a first imaginary line extending in the first direction and passing between the first opening and the third opening and a second imaginary line extending in the second direction and passing between the first opening and the second opening.

Abstract: The present invention provides a pharmaceutical composition for preventing or treating angiogenic diseases comprising inhibitors of NUP153 gene expression or NUP153 activity as active ingredient and a method for screening an agent for preventing or treating angiogenic diseases. According to the present invention, inhibition of the NUP153 gene expression or the NUP153 activity reduces export of mRNA of a pro-angiogenic factor (VEGF, HGF and bFGF) from nucleus. In addition, inhibition of the NUP153 gene expression or the NUP153 activity has effect that angiogenesis are inhibited by inhibition of invasion and tube formation in a dose-dependent manner without showing toxicity. Therefore, the pharmaceutical composition of the present invention may be used for preventing or treating a variety of angiogenesis-related diseases, and the method for screening of the present invention may be valuably used in finding a new agent for preventing or treating angiogenic diseases.

Abstract: Provided is a method for manufacturing a printed circuit board. The method for manufacturing the printed circuit board includes applying an adhesive on a support board, attaching an electronic device on the adhesive, forming an insulation layer for burying the electronic device, separating the insulation layer from the support board, forming a lower insulation layer under the insulation layer, and forming a via connected to terminals of the electronic device in the insulation layer or the lower insulation layer. Thus, since an adhesion material of an adhesion film does not remain between the internal circuit patterns, and the internal circuit patterns are not stripped by an adhesion force of the adhesion film, device reliability may be secured.

Abstract: An apparatus and method for driving a liquid crystal display device are disclosed in which the response speed of the liquid crystal can be increased without using a digital memory. The driving apparatus includes a liquid crystal panel with gate lines and data lines arranged perpendicularly to each other, a gate driver that supplies a gate pulse to the gate lines, and a data driver. The data driver samples an input N-bit digital data signal to generate an analog data voltage, generates a modulated data voltage for acceleration of a response speed of the liquid crystal according to an M-bit data value of the sampled digital data signal, mixes the modulated data voltage with the analog data voltage, and supplies the mixed data voltage to the data lines.